

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: David S. GARVEY et al. Confirmation No.: 7604  
Application No.: 10/568,819 Art Unit: 1626  
Filed: November 3, 2006 Examiner: S. L. Chung  
Title: NITROSATED AND NITROSYLATED CARDIOVASCULAR  
COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

Dear Madam:


In response to the restriction requirement set forth in the Office Action mailed March 17, 2009, Applicants hereby provisionally elect claims 1-6 and 13-17 for continued examination.

**I. Provisional Response to Restriction Requirement**


Applicants respectfully elect Examiner's Group I, with traverse, drawn to compounds of Formula (I).

In response to the election of species, Applicants provisionally elect 2,2-bis(nitrooxy)propyl 2-(N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoate, with traverse.

The compound has the following structure:



The compound is disclosed in the specification as the compound of Formula (I) wherein  $X_3$  is variable (1);  $Y_3$  is variable (2);  $Z_3$  is -CH;  $R_{10}$  is a hydrogen atom;  $D_4$  is a hydrogen;  $U_3$  is an oxygen; and  $D_1$  is:



The elected species is also disclosed as the compound of Formula (XIX), wherein  $T'$  is an oxygen,  $R_m$ - $R_n$  taken together are a hydrogen atom and  $R_n$  is variable (17).

Applicants believe no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 08-0219, under Order No. 0102258.00174US3 from which the undersigned is authorized to draw.

Respectfully submitted,

Dated: April 15, 2009

/Belinda M. Lew/  
 Belinda M. Lew, Ph.D.  
 Registration No.: 53,212  
 Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP  
 1875 Pennsylvania Avenue, NW  
 Washington, DC 20006  
 (202) 663-6000 (telephone)  
 (202) 663-6363 (facsimile)